• Small Molecules
    • Large Molecules
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

In the Media

Biologics Testing Highlights Need for Analytical Skills
3rd Jan, 2022
We are co-innovating with global pharma companies - Syngene MD & CEO
25th Dec, 2021
Manufacturing vaccines during Covid-19: CMOs/CDMOs to the rescue
11th Nov, 2021
Seeing good demand for biologics manufacturing- Syngene CEO Jonathan Hunt
25th Oct, 2021
Scientific breadth-depth of our portfolio contributing to developmentof new therapies- Mahesh Bhalgat
5th Oct, 2021
Syngene's client Panbela announces issuance of key U.S. patent for pancreatic cancer
9th Aug, 2021
Syngene CEO on what sets Indian CROs apart
8th Aug, 2021
Syngene's Hunt Says India Now Offers Intellectual Arbitrage to Firms
31st Jul, 2021
Remdesivir production boosted our June quarter growth strongly-Syngene CEO
22nd Jul, 2021
Syngene in Fortune India's Top 100 wealth creators list
7th Jul, 2021

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

To download, Please share your details

To download, Please share your details